There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio +1 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591
Recruiting
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Cincinnati, Ohio
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)
NCT06334419
Recruiting
This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded... Read More
Gender:
Male
Ages:
Between 18 years and 40 years
Trial Updated:
03/19/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Fragile X Syndrome
Register for Updates
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT05425940
Recruiting
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Exelixis Clinical Site #6, Cincinnati, Ohio
Conditions: Colorectal Cancer
Register for Updates
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
NCT04736121
Recruiting
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C. SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90 (Y-90), with a size between 20 and 60 microns in diameter. Y-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. SIR-Spheres are indicat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: University of Cincinnati Cancer Center CTO, Cincinnati, Ohio
Conditions: Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Cincinnati, Cincinnati, Ohio
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: The Lindner Research Center, Cincinnati, Ohio
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Cincinnati, Ohio
Conditions: Neoplasms
Register for Updates
FT576 in Subjects With Multiple Myeloma
NCT05182073
Recruiting
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Oncology Hematology Care, Inc, Cincinnati, Ohio
Conditions: Multiple Myeloma, Myeloma
Register for Updates
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
NCT05231668
Recruiting
SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI. Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks. There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be eva... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/13/2024
Locations: Cincinnati Children's Hospital Medical Center Site Number : 8400010, Cincinnati, Ohio
Conditions: Osteogenesis Imperfecta
Register for Updates
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375
Recruiting
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
03/13/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Register for Updates
COMPASSION S3 Post-Approval Study
NCT04860765
Recruiting
This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Cincinatti Children's Hospital, Cincinnati, Ohio
Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Register for Updates